Investigators from Spain, Italy and Canada now have evidence that cannabidiol (CBD) – a non-psychoactive chemical found in marijuana – exerts a combination of anti-cancer effects at the molecular level.
Published last month in the open-access journal PLOS One, the results provide “new insights into the antitumor action of CBD, showing that this cannabinoid affects multiple tumoral features and molecular pathways,” write the authors, who conducted experiments using CBD and glioma cell cultures.
“As CBD is a non-psychoactive phytocannabinoid that appears to be devoid of side effects, our results support its exploitation as an effective anti-cancer drug in the management of gliomas.”
While marijuana’s cancer-fighting potential is not a new discovery, interest has grown in recent years. Earlier this month, the drug company GW Pharmaceuticals announced the start of the first clinical trials involving cannabis-based medicine as a cancer therapy.
Dr. Massi and her colleagues have also conducted a number of earlier pre-clinical studies on cannabinoids and cancer, with funding from GW Pharmaceuticals.
- First Human Trials Using Cannabis To Treat Brain Cancer Under Way (sorendreier.com)
- Study: CBD Reduces Pain, Slows Breast Cancer (sfgate.com)